This observation is consistent with preclinical data reporting that BRAF inhibitor encorafenib suppressed MEK signaling but had no significant effect on ERK phosphorylation, while the combination of encorafenib and osimertinib significantly reduced both MEK and ERK phosphorylation, as well as growth of NSCLC cells harboring both EGFR and BRAF V600E mutations [30]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.